Ultrasound-guided injection of botulinum toxin type A blocks cardiac sympathetic ganglion to improve cardiac remodeling in a large animal model of chronic myocardial infarction

Zhang, Song; Wang, Meng; Jiao, Liying; Liu, Chengzhe; Chen, Huaqiang; Zhou, Liping; Wang, Yueyi; Wang, Yuhong; Liu, Zhihao; Liu, Zihan; Zhou, Yuyang; Zhou, Huixin; Xu, Xiaohong; Li, Zeyan; Yu, Zhenhua; Nie, Liqing; Yu, Lilei; Jiang, Hong

doi:10.1016/j.hrthm.2022.08.002

Cited by 13 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, a preclinical study demonstrated that injection of botulinum toxin A into the left stellate ganglion in a canine model of chronic myocardial infarction lead to inhibition of left stellate ganglion function, which improved heart rate variability and alleviated ventricular remodeling, ameliorated cardiac function, and prevented ventricular arrhythmias 30 days after induction of myocardial infarction. The ultrasound-guided percutaneous injection of botulinum toxin is noninvasive and therefore constitutes a clinically relevant approach [ 81 ] (Table 3 ).…”

Section: Recent Advances In Aad Therapiesmentioning

confidence: 99%

Recent Advances in Antiarrhythmic Drug Therapy

Saljic

Heijman

Dobrev

2023

Drugs

View full text Add to dashboard Cite

Cardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs (AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia management, despite moderate efficacy and the potential for significant adverse proarrhythmic effects. Due to conceptual, regulatory and financial considerations, the number of novel antiarrhythmic targets and agents in the development pipeline has decreased substantially during the last few decades. However, several promising candidates remain and there are exciting developments in repurposing and reformulating already existing drugs for indications related to cardiac arrhythmias. This review discusses the key conceptual considerations for the development of new antiarrhythmic agents, summarizes new compounds and formulations currently in clinical development for rhythm control of atrial fibrillation, and highlights the potential for drug repurposing. Finally, future directions in AAD development are discussed. Together with an ever-increasing understanding of the molecular mechanisms underlying cardiac arrhythmias, these components support a cautiously optimistic outlook towards improved pharmacological treatment opportunities for patients suffering from cardiac arrhythmias.

show abstract

Section: Recent Advances In Aad Therapiesmentioning

confidence: 99%

Recent Advances in Antiarrhythmic Drug Therapy

Saljic

Heijman

Dobrev

2023

Drugs

View full text Add to dashboard Cite

show abstract

“…Direct injection of botulinum toxin to the SG can inhibit left SG function and improve cardiac remodeling in a large animal model of chronic MI. 44 Lee et al. 45 used botulinum injection into the celiac plexus for celiac plexus block and found it is an effective alternative to RDN in managing refractory hypertension.…”

Section: Effects Of Neuromodulationmentioning

confidence: 99%

Autonomic Modulation of Atrial Fibrillation

Tsai

Hung

Kusayama

et al. 2023

JACC: Basic to Translational Science

View full text Add to dashboard Cite

“…These short- and long-term results demonstrate the basics for an attractive non-invasive, transitory, but still effective procedure. Another study performed in dogs to determine the potential effect of injections of BoNT-A (Botox) into the left stellate ganglion in post-myocardial infarction, demonstrated the inhibited function of the sympathetic nervous system, improved cardiac remodeling and function and prevention of ventricular arrhythmias, ultimately showing beneficial cardioprotective effects of the toxin [ 65 ].…”

Section: Therapeutic Applications In Veterinary Medicinementioning

confidence: 99%

Therapeutic Applications of Botulinum Neurotoxins in Veterinary Medicine

Turin,

Piccione,

Crosa

et al. 2023

Veterinary Sciences

View full text Add to dashboard Cite

Botulinum neurotoxins (BoNTs) are emerging as multipurpose therapeutic compounds for the treatment of several different syndromes involving peripheral and central nervous systems, and muscular and musculoskeletal disorders both in human and veterinary medicine. Therefore, the study of BoNTs is rapidly developing and identifying newly produced BoNT variants. Efforts should be made to clarify the biological and pharmacological characteristics of these novel BoNTs as well as the natural ones. The high potential of BoNTs as a therapeutic compound for medical syndromes lies in its ability to reach a specific cell type while bypassing other cells, thus having mild or no side effects. In this paper the recent developments in BoNTs are reviewed with the aim of analyzing the current knowledge on BoNTs’ biological mechanisms of action, immunogenicity, formulations, and therapeutic applications in the veterinary field, highlighting advantages and drawbacks and identifying the gaps to be filled in order to address research priorities.

show abstract

Ultrasound-guided injection of botulinum toxin type A blocks cardiac sympathetic ganglion to improve cardiac remodeling in a large animal model of chronic myocardial infarction

Cited by 13 publications

References 24 publications

Recent Advances in Antiarrhythmic Drug Therapy

Recent Advances in Antiarrhythmic Drug Therapy

Autonomic Modulation of Atrial Fibrillation

Therapeutic Applications of Botulinum Neurotoxins in Veterinary Medicine

Contact Info

Product

Resources

About